Hafiz Muhammad Mazhar Asjad
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Hafiz Muhammad Mazhar Asjad has a total of 17 co-authors. Here are the top co-authors by number of shared publications:
- Abdulhakeem S. Alamri
Department of Clinical Laboratory Sciences, Faculty of Applied Medical Sciences, Taif University, Taif, Saudi Arabia
1 shared publication - Amal F. Alshammary
Department of Clinical Laboratory Sciences, College of Applied Medical Sciences, King Saud University, Riyadh, Saudi Arabia
1 shared publication Amina Arshad
College of Pharmacy University of Sargodha Sargodha Pakistan
1 shared publication- Anjum Khusheed
Department of Pharmacy, Grand Asian University, Sialkot, Pakistan
1 shared publication - Ayisha Khalid
Faculty of Pharmacy and Allied Health Sciences, University of Balochistan, Quetta 83700, Pakistan
1 shared publication - Hammad Saleem
Institute of Pharmaceutical Sciences (IPS), University of Veterinary and Animal Sciences (UVAS), Lahore, Pakistan
1 shared publication
Latest Publications
- 5 December 2025
- Published by Wiley in Advanced Therapeutics
- Vol. 8 (12)
Zeta Potential Changing Self‐Emulsifying Drug Delivery Systems: A Promising Approach to Improve Oral Bioavailability of BCS Class IV Drugs by Overcoming Mucus Barriers via Enhanced Mucus Permeation and Cellular Uptake
The current study was designed to create drug‐loaded zeta potential shifting self‐emulsifying drug delivery systems (SEDDS) to improve oral bioavailability of poorly soluble drugs via enhancing their cellular absorption, mucus diffusion. For this purpose, phosphorylated oleylamine was added to SEDDS at 2% (v/v) concentration that contained Cremophor EL, Labrasol, Tween 80, miglyol, propylene glycol, and Captex 355. The cytotoxicity of drug‐loaded phosphorylated oleylamine‐containing SEDDS was examined on Caco‐2 cells. Moreover, phosphate cleavage via alkaline phosphatase (AP) was used to measure phosphate release. Simultaneously, mucus diffusion, shift in zeta potential, and cellular uptake studies were executed. Furthermore, proof‐of‐concept in vivo studies were conducted to evaluate oral bioavailability. Phosphorylated oleylamine was created by amide bond formation between oleylamine and 6‐phosphogluconic acid via carbodiimide chemistry. The droplet size and zeta potential of phosphorylated SEDDS were 67 nm and −12.71 mV, respectively. After 6 h of incubation with AP, a rapid phosphate release and charge reversal were observed from phosphorylated oleylamine‐containing SEDDS. Moreover, phosphorylated SEDDS demonstrated 3.1‐fold enhanced mucus penetration and 3.24‐fold enhanced cellular uptake in comparison to the control. Furthermore, in vivo studies exhibited a 9.2‐fold enhanced relative oral bioavailability. Based on enhanced drug mucus diffusion, cellular uptake, and oral bioavailability, it can be estimated that drug‐loaded phosphorylated oleylamine‐containing SEDDS can be a vital tool to improve oral bioavailability of BCS Class IV drugs.
- 5 December 2025
- Published by Wiley in Advanced Therapeutics
- Vol. 8 (12)
Zeta Potential Changing Self‐Emulsifying Drug Delivery Systems: A Promising Approach to Improve Oral Bioavailability of BCS Class IV Drugs by Overcoming Mucus Barriers via Enhanced Mucus Permeation and Cellular Uptake
The current study was designed to create drug‐loaded zeta potential shifting self‐emulsifying drug delivery systems (SEDDS) to improve oral bioavailability of poorly soluble drugs via enhancing their cellular absorption, mucus diffusion. For this purpose, phosphorylated oleylamine was added to SEDDS at 2% (v/v) concentration that contained Cremophor EL, Labrasol, Tween 80, miglyol, propylene glycol, and Captex 355. The cytotoxicity of drug‐loaded phosphorylated oleylamine‐containing SEDDS was examined on Caco‐2 cells. Moreover, phosphate cleavage via alkaline phosphatase (AP) was used to measure phosphate release. Simultaneously, mucus diffusion, shift in zeta potential, and cellular uptake studies were executed. Furthermore, proof‐of‐concept in vivo studies were conducted to evaluate oral bioavailability. Phosphorylated oleylamine was created by amide bond formation between oleylamine and 6‐phosphogluconic acid via carbodiimide chemistry. The droplet size and zeta potential of phosphorylated SEDDS were 67 nm and −12.71 mV, respectively. After 6 h of incubation with AP, a rapid phosphate release and charge reversal were observed from phosphorylated oleylamine‐containing SEDDS. Moreover, phosphorylated SEDDS demonstrated 3.1‐fold enhanced mucus penetration and 3.24‐fold enhanced cellular uptake in comparison to the control. Furthermore, in vivo studies exhibited a 9.2‐fold enhanced relative oral bioavailability. Based on enhanced drug mucus diffusion, cellular uptake, and oral bioavailability, it can be estimated that drug‐loaded phosphorylated oleylamine‐containing SEDDS can be a vital tool to improve oral bioavailability of BCS Class IV drugs.
- 23 October 2025
- Published by World Scientific Pub Co Pte Ltd in Journal of Computational Biophysics and Chemistry
- Vol. 25 (11) , 1595-1616
A Comprehensive Investigation of Dracaena Deremensis Extracts: Phytochemical Composition, Multi-Faceted Biochemical Propensities, ADMET and Computational Analysis
In this study, dichloromethane (DD-D) and methanolic (DD-M) extracts of Dracaena deremensis were comprehensively investigated for their phytochemical composition, antioxidant, antimicrobial, enzyme inhibition and computational properties. Preliminary phytochemical screening revealed the presence of various secondary metabolites, including alkaloids, flavonoids, phenols, steroids, cardiac glycosides and quinones. Quantitative analysis showed higher alkaloid content in both extracts, with DD-M (8.66 mg AE/g) slightly outperforming DD-D (7.61 mg AE/g). GC-MS profiling identified 54 compounds in DD-M and 48 in DD-D, representing diverse phytochemical classes. Both extracts exhibited strong antioxidant activity (DPPH, TAC, FRAP and NO assays) and notable antimicrobial effects against E. coli, S. typhi, K. pneumoniae, S. aureus and S. cerevisiae. Significant enzyme inhibition was observed against [ ]-glucosidase and tyrosinase, with moderate effects on AchE, BchE and LOX. Four key compounds, i.e. DC13, DC14, DC8 and MT16 demonstrated strong binding affinities in molecular docking simulations, supported by DFT-based HOMO-LUMO analysis and molecular dynamics studies, which confirmed stable binding conformations and favorable energetics. These results underscore D. deremensis as a promising source of multifunctional bioactive compounds, with potential applications in managing oxidative stress, microbial infections, neurodegeneration and metabolic disorders.
- 23 October 2025
- Published by World Scientific Pub Co Pte Ltd in Journal of Computational Biophysics and Chemistry
- Vol. 25 (11) , 1595-1616
A Comprehensive Investigation of Dracaena Deremensis Extracts: Phytochemical Composition, Multi-Faceted Biochemical Propensities, ADMET and Computational Analysis
In this study, dichloromethane (DD-D) and methanolic (DD-M) extracts of Dracaena deremensis were comprehensively investigated for their phytochemical composition, antioxidant, antimicrobial, enzyme inhibition and computational properties. Preliminary phytochemical screening revealed the presence of various secondary metabolites, including alkaloids, flavonoids, phenols, steroids, cardiac glycosides and quinones. Quantitative analysis showed higher alkaloid content in both extracts, with DD-M (8.66 mg AE/g) slightly outperforming DD-D (7.61 mg AE/g). GC-MS profiling identified 54 compounds in DD-M and 48 in DD-D, representing diverse phytochemical classes. Both extracts exhibited strong antioxidant activity (DPPH, TAC, FRAP and NO assays) and notable antimicrobial effects against E. coli, S. typhi, K. pneumoniae, S. aureus and S. cerevisiae. Significant enzyme inhibition was observed against [ ]-glucosidase and tyrosinase, with moderate effects on AchE, BchE and LOX. Four key compounds, i.e. DC13, DC14, DC8 and MT16 demonstrated strong binding affinities in molecular docking simulations, supported by DFT-based HOMO-LUMO analysis and molecular dynamics studies, which confirmed stable binding conformations and favorable energetics. These results underscore D. deremensis as a promising source of multifunctional bioactive compounds, with potential applications in managing oxidative stress, microbial infections, neurodegeneration and metabolic disorders.